Richard M. Wright
Known title: SR. VP & CCOCIK: 0001646423
Associated companies
Transaction History
| CLDX | ▲ Buy | Option Exercise | 6,876 | $62K | 11/13/2025 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 26,672 | $277K | 11/13/2025 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 15,750 | $354K | 11/13/2025 | View on chart |
| CLDX | ▼ Sell | Open Market | 49,298 | $1.2M | 11/13/2025 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 20,625 | $57K | 6/3/2024 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 28,469 | $797K | 6/3/2024 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 18,375 | $413K | 6/3/2024 | View on chart |
| CLDX | ▼ Sell | Open Market | 27,580 | $925K | 6/3/2024 | View on chart |
| CLDX | ▼ Sell | Open Market | 19,264 | $655K | 6/3/2024 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 15,328 | $159K | 8/15/2022 | View on chart |
| CLDX | ▼ Sell | Open Market | 15,328 | $578K | 8/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 24, 2026
Celldex shares dip after positive Phase 3 barzolvolimab results
Celldex reported that its drug barzolvolimab met endpoints in Phase 3 trials for chronic spontaneous urticaria, showing durable responses. Despite these positive results, the stock fell 11%, with some analysts noting that safety concerns appear misplaced. Major firms like Morgan Stanley and Leerink Partners recently raised their price targets, while the company continues to manage a high cash burn rate.
Celldex shares dip after positive Phase 3 barzolvolimab results. Celldex reported that its drug barzolvolimab met endpoints in Phase 3 trials for chronic spontaneous urticaria, showing durable responses. Despite these positive results, the stock fell 11%, with some analysts noting that safety concerns appear misplaced. Major firms like Morgan Stanley and Leerink Partners recently raised their price targets, while the company continues to manage a high cash burn rate.